Want to see VYGR full AI Analyst Report?

Voyager Therapeutics (VYGR) Price & Analysis

1,379 Followers

VYGR Stock Chart & Stats

$4.13

-$0.14(-2.36%)

At close: Jan 08 4:00 PM EST

$4.13

-$0.14(-2.36%)

Day’s Range― - ―

52-Week Range$2.83 - $5.55

Previous CloseN/A

Volume91.62K

Average Volume (3M)559.62K

Market Cap

$228.39M

Enterprise Value$209.98M

Total Cash (Recent Filing)$141.48M

Total Debt (Recent Filing)$34.57M

Price to Earnings (P/E)―

Beta1.32

Next Earnings

Jul 30, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.98

Shares Outstanding60,421,288

10 Day Avg. Volume497,477

30 Day Avg. Volume559,615

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.18

Price to Sales (P/S)5.71

P/FCF Ratio-1.71

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue5.75

Enterprise Value/Gross Profit-6.64

Enterprise Value/Ebitda-1.87

Forecast

1Y Price Target

$17.00

Price Target Upside311.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.7

Revenue Forecast (FY)$42.03M

Bulls Say, Bears Say

Bulls Say

Pipeline Progress (IND Clearance)Regulatory clearance of the VY1706 IND materially de-risks Voyager’s Alzheimer’s program and creates a clear clinical path. IND clearance enables collection of safety/biomarker data, strengthens partnership and financing prospects, and validates platform capabilities long-term.

Conservative LeverageLow debt relative to equity reduces near-term refinancing and interest burdens for a clinical-stage biotech. Manageable leverage preserves flexibility to raise capital or structure partnerships and lowers bankruptcy risk while the company executes expensive clinical programs.

High Gross MarginsExtremely high gross margins suggest the company’s revenue sources or collaboration economics are high-value and scalable. If operating spend is rebalanced or partnered programs advance, margin structure supports pathway to improved profitability and attractive unit economics over time.

Bears Say

Large Cash Burn / Negative FCFSustained, large negative operating and free cash flow creates significant funding risk for a pre-revenue biotech. Ongoing burn forces dependence on external financing, can delay programs if capital tightens, and materially increases dilution risk absent near-term partnerships or non-dilutive funding.

Profitability Deterioration And Revenue DeclineSharp deterioration in profitability and declining revenue indicate operating expenses have outpaced value capture. This volatile earnings profile undermines internal funding ability, pressures returns, and means the company must demonstrate clinical progress to reverse fundamental weakness.

Equity Erosion And Reliance On External CapitalDoubling authorized shares and prior equity declines reflect a reliance on equity-capital markets to fund operations. While providing optionality, this structural dependence signals potential future dilution and highlights limited retained-capital buffers if clinical milestones are delayed.

Voyager Therapeutics News

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

The latest update is out from Voyager Therapeutics ( ($VYGR) ). On June 9, 2026, Voyager Therapeutics, Inc....

26d ago

VYGR

Voyager Therapeutics announces FDA clearance for VY1706 IND application

Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706,...

1M ago

VYGR

Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy

The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1, 2026, Voyager Therapeutics, Inc....

1M ago

VYGR

Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

1M ago

VYGR

Voyager awarded new mission management contract with Exobiosphere

Voyager Technologies and Exobiosphere announced a mission management contract on the International Space Station that marks a concrete...

2M ago

VYGR

Voyager Therapeutics presents GLP for toxicology data for VY1706

Voyager Therapeutics (VYGR) presented three-month good laboratory practice, or GLP, toxicology data for VY1706, the Company’s investigational tau...

2M ago

VYGR

Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings

Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Regulation category. Voyager Therapeutics Inc. is exposed...

2M ago

VYGR

Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on...

2M ago

VYGR

Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)

Reports Q1 revenue $2.59M, consensus $8.79M. “As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager...

2M ago

VYGR

Voyager Therapeutics management to meet with Oppenheimer

Meeting to be held on April 28 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

2M ago

VYGR

Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes

Voyager Therapeutics ( ($VYGR) ) has shared an update. On April 15, 2026, Voyager Therapeutics, Inc. announced that...

3M ago

VYGR

Amazon (AMZN) Launches AI Tools to Help Accelerate Drug Discoveries

Companies are increasingly turning to AI for new medicines. ...

3M ago

NVO

AMZN

Voyager Therapeutics management to meet with Oppenheimer

Meeting to be held on April 13 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

VYGR

Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Samantha Semenkow from...

3M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics Inc.’s price range in the past 12 months?

Voyager Therapeutics Inc. lowest stock price was $2.83 and its highest was $5.55 in the past 12 months.

What is Voyager Therapeutics Inc.’s market cap?

Voyager Therapeutics Inc.’s market cap is $228.39M.

When is Voyager Therapeutics Inc.’s upcoming earnings report date?

Voyager Therapeutics Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.

How were Voyager Therapeutics Inc.’s earnings last quarter?

Voyager Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.081.

Is Voyager Therapeutics Inc. overvalued?

According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics Inc. pay dividends?

Voyager Therapeutics Inc. does not currently pay dividends.

What is Voyager Therapeutics Inc.’s EPS estimate?

Voyager Therapeutics Inc.’s EPS estimate is -0.5.

How many shares outstanding does Voyager Therapeutics Inc. have?

Voyager Therapeutics Inc. has 60,421,288 shares outstanding.

What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?

Voyager Therapeutics Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went up 2.273%.

Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?

Currently, no hedge funds are holding shares in VYGR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-55.97%

Trailing 12-Months

Asset Growth

-37.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics Inc.

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$17.00

▲(311.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,5.246153846153846,6.892307692307693,8.538461538461538,10.184615384615384,11.83076923076923,13.476923076923077,15.123076923076923,16.76923076923077,18.415384615384614,20.06153846153846,21.70769230769231,23.353846153846156,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,4.630769230769231,5.661538461538462,6.692307692307693,7.723076923076924,8.753846153846155,9.784615384615385,10.815384615384616,11.846153846153847,12.876923076923077,13.907692307692308,14.938461538461539,15.969230769230771,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,3.9384615384615387,4.276923076923077,4.615384615384615,4.953846153846154,5.292307692307693,5.63076923076923,5.969230769230769,6.307692307692308,6.6461538461538465,6.984615384615385,7.323076923076924,7.661538461538461,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >